Abstract: The present invention provides a method of figuring out an effect of a medicine exerting on the same cell quantitatively over a time. A cell evaluation method includes a step of culturing cells on a cell-culture base material that is capable of culturing spheroids, and a step of measuring a change over a time in the number of the spheroids formed through the former step or a percentage of the spheroids formed through the former step relative to an entire cultured cell.

Abstract: It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B): (A) a peptide, which has the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells.

Abstract: It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B): (A) a peptide, which has the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells.

Abstract: The object of the present invention is to find out another tumor marker which is useful for early diagnosis of melanoma, and provide a diagnostic kit and diagnostic method for malignant melanoma using such marker. The present invention provides a diagnostic kit for malignant melanoma, which comprises an antibody against SPARC and an antibody against GPC3.

Abstract: An object of the present invention is to provide a novel and clinically useful diagnostic agent for malignant melanoma. The present invention provides a diagnostic agent for malignant melanoma, which comprises an antibody against GPC3, or a probe or a primer capable of detecting GPC3 expression.

Abstract: It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B): (A) a peptide, which has the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells.

Abstract: The object of the present invention is to find out another tumor marker which is useful for early diagnosis of melanoma, and provide a diagnostic kit and diagnostic method for malignant melanoma using such marker. The present invention provides a diagnostic kit for malignant melanoma, which comprises an antibody against SPARC and an antibody against GPC3.

Abstract: An object of the present invention to provide: a human pancreatic cancer antigen and/or a human colon cancer antigen that can be applied to the diagnosis and/or treatment of various types of cancers or tumors including pancreatic cancer and colon cancer as representative examples; a gene encoding the same; an anti-cancer vaccine using the same; or the like. The present invention provides a cancer antigen comprising a protein having the amino acid sequence shown in SEQ ID NO: 1; a peptide comprising a portion of said protein and having immune-stimulating activity; an anti-cancer vaccine comprising said peptide; a DNA having the nucleotide sequence shown in SEQ ID NO: 2, or its complementary sequence or a part or full length of these sequence; an anti-cancer vaccine comprising said DNA; and use thereof.

Abstract: An object of the present invention is to provide a novel and clinically useful diagnostic agent for malignant melanoma. The present invention provides a diagnostic agent for malignant melanoma, which comprises an antibody against GPC3, or a probe or a primer capable of detecting GPC3 expression.

Abstract: An object of the present invention to provide: a human pancreatic cancer antigen and/or a human colon cancer antigen that can be applied to the diagnosis and/or treatment of various types of cancers or tumors including pancreatic cancer and colon cancer as representative examples; a gene encoding the same; an anti-cancer vaccine using the same; or the like. The present invention provides a cancer antigen comprising a protein having the amino acid sequence shown in SEQ ID NO: 1; a peptide comprising a portion of said protein and having immune-stimulating activity; an anti-cancer vaccine comprising said peptide; a DNA having the nucleotide sequence shown in SEQ ID NO: 2, or its complementary sequence or a part or full length of these sequence; an anti-cancer vaccine comprising said DNA; and use thereof.